News

Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor–positive early breast cancer in ...
Aromatase inhibitors act through pure oestrogen deprivation to achieve an endocrine response in oestrogen receptor (ER)-positive breast cancer. Both experimental and clinical data now confirm that ...
Aromatase inhibitors (AIs), like arimidex, aromasin and femara, are also used to help fight cancer cell regrowth. These drugs work to block cell receptors like estrogen and progesterone in breast ...
Researchers analyzed the effectiveness of aromatase inhibitors by looking at the results of four different trials. Their findings were recently presented at the 2021 San Antonio Breast Cancer ...
Aromatase inhibitors for breast cancer: Advantages over tamoxifen in early-stage disease Longer survival, later recurrences/ Evidence for late-stage disease much poorer ...
Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...
Aromatase inhibitors were just as effective in women aged under 35, who have a higher risk of recurrence than older women. There was no apparent difference in the number of deaths from breast ...
Aromatase inhibitors, such as letrozole, are newer and alter the function of aromatase, an enzyme involved in oestrogen production. They can be used in sequence with, ...
A number of adjuvant breast cancer trials are currently evaluating all 3 third-generation aromatase inhibitors relative to the current standard, tamoxifen for 5 years. In comparing efficacy and ...
Aromatase inhibitors are not appropriate for premenopausal patients for a number of reasons. First, higher circulating levels of androgens present in premenopausal women compete with aromatase ...
I have been on an aromatase inhibitor for the past eight months and have side effects that keep me from having a good quality of life. I am supposed to be on it for five years, but I do not want ...
Aromatase inhibitors were originally developed for the treatment of estrogen-receptor-positive breast cancer, 1 and these drugs have been used in clinical trials for other conditions in children ...